Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations
Patent No. EP4025188 (titled "Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations") was filed by Janssen Pharmaceutica on May 7, 2021. The application was issued on Jan 10, 2024.
Patent Summary
Paliperidone palmitate for treating psychosis, schizophrenia, schizoaffective disorder, and bipolar disorder through a novel dosing strategy that enables continuous treatment with once-monthly injections. The dosing regimen involves administering a re-initiation loading dose of the extended-release formulation after a minimum six-month gap from the initial injection, followed by maintenance doses. This approach addresses the common challenge of medication adherence by providing a continuous therapeutic effect while minimizing the need for frequent clinic visits.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4025188
- Application Number
- EP21724652A
- Filing Date
- May 7, 2021
- Status
- Granted And Under Opposition
- Dec 8, 2023
- Publication Date
- Jan 10, 2024
- External Links
- Slate, Register , Google Patents